pondence is byjng deposited in the U.S. Patent and Trademark Office via facsimile transmittal to (703) 872-9306.

Appl. No. 10/076,248 Reply to Office action of January 24, 2005 Response dated May 24, 2005

MAY 2 4 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

: 10/076,248

Confirmation No.: 6317

Applicant.

: MITCHELL et al.

Filed

: February 12, 2002

TC/A.U.

: 1637

Examiner

Cynthia B. Wilder

Docket No.

: 027705.00004

05/25/2005 BBONNER 00000038 10076248

01 FC:2814

Customer No.

38485

65.00 Op

For

: METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME

MEDIATED RNA TRANS-SPLICING

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TERMINAL DISCLAIMER PURSUANT TO 37 C.F.R. 37 C.F.R. L321(c)

Sir:

Intronn, Inc., the owner of the entire interest in U.S. Application Serial No. 10/076,248 filed on February 12, 2001 entitled "Methods and Compositions for use in Splicesome Mediated RNA Trans-Splicing", which is a continuation-in-part of pending application 09/838,858 filed April 20, 2001, which is a continuation-in-part-of pending application serial number 09/756,096 filed January 8, 2001, which is a continuation-inpart of pending application serial number 09/158,863 filed September 23, 1998, which issued as U.S. Patent No. 6,280,978, which is a continuation-in-part of serial number 09/133,717 filed on August 13, 1998, which issued as U.S. Patent No. 6,083,702, which is a continuation-in-part of serial number 09/087,233 filed on May 28, 1998, now

Appl. No. 10/076,248 Reply to Office action of January 24, 2005 Response dated May 24, 2005

abandoned, which is a continuation-in-part of pending application social number 08/766,354 filed on December 13, 1996, which issued as U.S. Patent No. 6,013,487, which claims benefit to provisional application number 60/008,717 filed on December 15, 1995, as evidenced by an assignment to Intronn, Inc., recorded in the U.S. Patent and Trademark Office on July 30, 2002 at Reel/Frame No. 013136 / 0119, hereby disclaims the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term, defined in 35 U.S.C. § 154 to 156 and 173, of commonly owned issued U.S. Patent No. 6,013,487. The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified application and granted U.S. Patent No. 6,013,487 are commonly owned. This agreement shall run with any patent granted on the instant application and shall be binding upon the assignces, their successors, or assigns.

The undersigned is attorney of record and has the authority to execute this

Terminal Disclaimer on behalf of Intronn, Inc., and has reviewed the above-referenced assignments and hereby certifies that, to the best of my knowledge and belief, title is in the assignces on whose behalf this terminal disclaimer is being filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title

Appl. No. 10/076,248 Reply to Office action of January 24, 2005 Response dated May 24, 2005

18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Payment of the filing fee in the amount of \$65.00, pursuant to 37 C.F.R. §1.20 (d), is to be made according to the Credit Card Payment Form attached herewith.

Applicants believe that no additional fees are required in connection with this filing.

However, if additional fees are required, the Commissioner is hereby authorized to charge any additional payment, or credit any overpayment, to Deposit Account No. 01-2300, referencing Docket Number 027705.00004.

Respectfully submitted,

Rochelle K. Seide, Ph.D Registration No. 32,300 ARENT FOX PLLC 1675 Broadway

New York, NY 10019

Tel. No. (212) 484-3945 Fax No. (212) 484-3990

Customer No. 004372